May 15th - 16th, 2019 (London, UK)

Injectable Drug Delivery Conference 2019

The SMi Group is pleased to announce the second annual Injectable Drug Delivery conference which will be held in London on the 15th and 16th May 2019.

The global injectable drug delivery market is expected to grow from $400 billion to $1200 billion by 2046 with a CAGR of 12.8%.

Injectable drug delivery is a method of drug administration into the body with a needle via various routes including intramuscular and intravenous. These are examples of conventional drug delivery. Recently, there has been a focus on novel drug delivery, including needle-free injectors, and transdermal patches. Long acting injectables (LAI) are developing fast as a push towards patient centric devices drives the industry. Habitually, injectables were used for delivery of hormones, vaccines and insulin but as technology advances the application is continuing to expand. Now there is an emphasis on finding solutions to chronic conditions and the biological drugs required involve formulation development challenges for proteins, including high viscosity and high volume. Self-administrative, connected, and ergonomic devices are the new drive. Self-injectable devices include pen injectors for diabetic patients. The wealth of expansion available in the field of connected devices is huge. The regulatory landscape is challenging as it evolves rapidly with the market demand for new devices.


Benefits of attending:

Developing on last years success, this event assembles an international audience to include regulatory, device design, packaging and formulation professionals. The devices need to be designed for the new generation of drugs and they need to provide safety with a strong patient focus. This event is will help inspire you to help drive this industry forward and learn about the predicted market trends, critical digital and chemical developments and the push for patient compliance in a changing regulatory landscape.

This conference offers a chance to learn about innovative injectable drug delivery systems with industrial insights on the following:

  • Life cycle management for developing devices that are both user friendly and revenue effective
  • Device design considerations
  • Long acting injectables and bringing these therapeutics to market with case studies
  • Connected devices, GDPR and cyber security programs
  • Developments in primary packaging
  • Growth in transdermal delivery and subcutaneous infusion devices
  • Digital health partnerships
  • Large volume patch pump innovation examples


Who should attend:

Executives, Directors, VPs, Heads, Principals, Managers, Scientists, Researchers of:

  • Autoinjectors
  • Wearables
  • Device Engineering
  • Human Factors
  • CMC
  • Injectables
  • Sterile Manufacturing
  • Packaging
  • Regulatory Affairs


AbbVie; Aptar France SAS; AstraZeneca; Barts Health NHS Trust; Cambridge Consultants Ltd; Cambridge Design Partnership; Cantab Innovations; Credence MedSystems; Crux Product Design, Ltd; Enable Injections; Enesi Pharma Ltd; F. Hoffmann-La Roche Ltd; Fresenius Kabi Deutschland GmbH; GSK; Human Factors Centre Ltd; IPSEN; Janssen; KCL; LEO Pharma A/S; Mallinckrodt Pharmaceuticals; MedinCell; MHRA; New Injection Systems Ltd; Novaliq GmbH; Novartis Pharma GmbH; Owen Mumford; Pfizer; Phillips - Medisize; Phillips-Medisize; Roche Pharmaceuticals; Sanofi-Aventis; Sanofi-Aventis R&D; University College London; UroPharma Limited; W.L. Gore & Associates, Inc.; Weidmann Medical Technology Ag; Worrell;

Share this post

Submit to FacebookSubmit to Google PlusSubmit to TwitterSubmit to LinkedIn